Intraocular Povidone-Iodine During Pars Plana Vitrectomy for Severe and Atypical Endophthalmitis
Recommended Citation
Rahmani K, Saad M, Le K, and Lin X. Intraocular Povidone-Iodine During Pars Plana Vitrectomy for Severe and Atypical Endophthalmitis. Retina 2025.
Document Type
Article
Publication Date
12-9-2025
Publication Title
Retina (Philadelphia, Pa.)
Abstract
PURPOSE: To evaluate the use of povidone-iodine (PI) infusion during pars plana vitrectomy (PPV) and to assess its clinical outcomes in the treatment of severe endophthalmitis.
METHODS: A retrospective case series of 40 patients (41 eyes) with clinically or culture-confirmed endophthalmitis underwent PPV with 0.025% PI in the infusion solution. Outcomes included infection resolution, improvements in visual acuity, the need for additional surgeries, and signs of ocular toxicity.
RESULTS: Of the 41 eyes treated, infection resolved in 33 (80.4%) eyes postoperatively. Visual acuity improved postoperatively in 29 eyes (70.7%). Mean uncorrected visual acuity improved from 20/3337 (2.22 ± 0.70 logMAR) preoperatively to 20/540 (1.43 ± 0.88 logMAR) postoperatively (P < 0.0001). No ocular toxicity or unexplained vision loss related to PI infusion was observed.
CONCLUSIONS: The addition of 0.025% PI infusion during PPV appears safe and led to favorable post-surgical outcomes in a traditionally high-risk cohort.
PubMed ID
41481923
ePublication
ePub ahead of print
